GlassScriptPhysician profile
James G Powell
NPI 1164523932
$88,351.10
in general payments reported to CMS, 2019-2025
40 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $12K · 2021: $9,583 · 2022: $1,571 · 2023: $1,607 · 2024: $1,504 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,423.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $80,382.57 | 2019-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $842.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $811.26 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Sanofi-Aventis U.S. LLC | $807.31 | 2019-2025 | |
| Abbott Laboratories | $801.81 | 2019-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $642.36 | 2019-2025 | Jardiance |
| Dexcom, INC. | $605.00 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $516.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $265.37 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.47 | 2022-2025 | |
| Radius Health, INC. | $170.41 | 2019-2024 | |
| Insulet Corporation | $156.59 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $153.20 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $135.34 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $127.21 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $119.01 | 2021-2023 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $115.91 | 2023-2024 | |
| Pfizer INC. | $115.02 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $106.87 | 2019-2020 | |
| Lifescan, INC. | $106.50 | 2021-2022 | |
| Sequel Med Tech, LLC | $102.02 | 2025 | Twiist |
| Becton, Dickinson and Company | $98.29 | 2019-2020 | |
| Medtronic Minimed, INC. | $97.68 | 2019-2020 | |
| Corcept Therapeutics | $93.00 | 2019-2023 | Korlym |
| Ascendis Pharma Endocrinology INC | $90.53 | 2024-2025 | Yorvipath |
| Ibsa Pharma INC. | $87.57 | 2022-2024 | Tirosint, Licart, Tirosint |
| Regeneron Healthcare Solutions, INC. | $87.46 | 2019-2023 | Praluent, Evkeeza |
| Beta Bionics, INC. | $84.72 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amarin Pharma, INC. | $84.66 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $61.17 | 2024 | Isturisa, Signifor Lar |
| Grt US Holding, INC. | $59.18 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $52.73 | 2020-2024 | Unithroid |
| Rgh Enterprises LLC | $40.08 | 2025 | |
| Horizon Therapeutics Plc | $33.77 | 2022-2023 | Tepezza |
| Shire North American Group INC | $31.86 | 2019 | |
| Averitas Pharma INC. | $31.16 | 2025 | Qutenza |
| Neurocrine Biosciences, INC. | $18.58 | 2024 | Ingrezza |
| Kyowa Kirin, INC. | $17.04 | 2023 | Crysvita |
| Acerus Pharmaceuticals Corporation | $15.63 | 2022 | |
| Dynavax Technologies Corporation | $9.11 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.